Skip to main content
Nasia Safdar, MD, Infectious Disease, Madison, WI

Nasia Safdar MD

Infectious Disease•Madison, WI

Assistant Professor, Medicine, University of Wisconsin Medical School

Join to View Full Profile

  • 600 Highland AveMadison, WI 53792

  • Phone+1 608-263-0943

  • Fax+1 608-265-8885

Dr. Safdar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Safdar's Full ProfileAlready have an account?

Education & Training

  • University of Wisconsin Hospitals and Clinics
    University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 2002 - 2003
  • University of Wisconsin Hospitals and Clinics
    University of Wisconsin Hospitals and ClinicsFellowship, Infectious Disease, 2000 - 2002
  • University of Wisconsin Hospitals and Clinics
    University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1997 - 2000
  • Aga Khan Medical College
    Aga Khan Medical CollegeClass of 1995

Certifications & Licensure

  • WI State Medical License
    WI State Medical License 1999 - 2027
  • Infectious Disease
    American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
  • CMS Meaningful Use Stage Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
  • CMS Meaningful Use Stage Stage 2 Certification EpicCare Inpatient EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Fecal Microbiota Transplantation for the Treatment of Recurrent and Severe Clostridium Difficile Infection in Solid Organ Transplant Recipients: A Multicenter Experience  
    Raj Vuppalanchi, Adam Ehrlich, Michael Smith, Asif Sharfuddin, Nasia Safdar, Nirmal Kaur, Elizabeth Ann Misch, Monika Fischer, Ann Flynn, Vincent Ganapini, Michael H W..., American journal of transplantation
  • Research Agenda for Microbiome Based Research for Multidrug-Resistant Organism Prevention in the Veterans Health Administration System  
    Dale N Gerding, Loreen Herwaldt, Daniel J Diekema, Nasia Safdar, Matthew Samore, Infection Control and Hospital Epidemiology
  • Setting the Research Agenda for Preventing Infections from Multidrug-Resistant Organisms in the Veterans Health Administration  
    Eli N Perencevich, Nasia Safdar, Infection Control and Hospital Epidemiology

Abstracts/Posters

  • Using Virus Sequencing to Determine Source of SARS-CoV-2 Transmission for Healthcare Worker
    Nasia Safdar, MD, Centers for Disease Control and Prevention, Orlando, FL, 12/9/2019

Authored Content

  • Hospital-Acquired Infections Are Rising – Here’s How to Protect Yourself in Health Care SettingsJuly 2024
  • Using Virus Sequencing to Determine Source of SARS-CoV-2 Transmission for Healthcare WorkerAugust 2020
  • The Wrong Frame of MindMay 2018

Press Mentions

  • ‘Vaccines Don’t Save Lives. Vaccinations Do’: Experts Talk Vaccine Safety, Misinformation
    ‘Vaccines Don’t Save Lives. Vaccinations Do’: Experts Talk Vaccine Safety, MisinformationOctober 30th, 2025
  • Prophylactic Vancomycin May Reduce Risk for Recurrent C. Difficile
    Prophylactic Vancomycin May Reduce Risk for Recurrent C. DifficileJuly 17th, 2025
  • Despite Vancomycin's Performance Against Placebo, Both Options Had Relatively High CDI Recurrence Rates 8 Weeks After Treatment Completion in 81 Patients Randomized to Either Prophylactic Oral Vancomycin or Placebo (43.6% vs 57.1%,
    Despite Vancomycin's Performance Against Placebo, Both Options Had Relatively High CDI Recurrence Rates 8 Weeks After Treatment Completion in 81 Patients Randomized to Either Prophylactic Oral Vancomycin or Placebo (43.6% vs 57.1%,July 2nd, 2025

Grant Support

  • Dietary Fiber-Microbiome Interactions: Elucidating Mechanisms to Suppress Multi-Drug Resistant Organisms in the Human GutDUKE UNIVERSITY2025–2029
  • BCCMA: Targeting Gut-Microbiome in Veterans Deployment related Gastrointestinal and Liver diseases; CMA5- Functional metagenomics in GWI-related gut dysfunctionWM S. MIDDLETON MEMORIAL VETERANS HOSP2023–2027

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Nasia Safdar, Dr. Nasia Safdar, MD, Dr. N Safdar